AD is a multifactorial disease, yet at present most therapeutic approaches have focused on single targets such as elimination of tau and amyloid accumulation in the brain, with only a small amount of success for long-term reversal of cognitive dysfunction [56–59]. Here, MAPT is linked to amyloidosis.